Figure 1 | Scientific Reports

Figure 1

From: Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients

Figure 1

Plasma imatinib levels predict early molecular response at 3 & 6 months and MMR at 12 months post imatinib therapy. (a) Plasma imatinib levels (median, range) on day29 with early molecular response at 3 months and (b) in patients with and without MMR to imatinib at 12 months. Statistical significance was calculated using Mann–Whitney U test.

Back to article page